The burden and risks of emerging complications of diabetes mellitus
D Tomic, JE Shaw, DJ Magliano - Nature Reviews Endocrinology, 2022 - nature.com
The traditional complications of diabetes mellitus are well known and continue to pose a
considerable burden on millions of people living with diabetes mellitus. However, advances …
considerable burden on millions of people living with diabetes mellitus. However, advances …
American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and …
K Cusi, S Isaacs, D Barb, R Basu, S Caprio… - Endocrine Practice, 2022 - Elsevier
Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
ME Rinella, BA Neuschwander-Tetri, MS Siddiqui… - Hepatology, 2023 - journals.lww.com
Abbreviations: AASLD, American Association for the Study of Liver Diseases; AI, artificial
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
intelligence; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC …
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta …
J Quek, KE Chan, ZY Wong, C Tan, B Tan… - The lancet …, 2023 - thelancet.com
Background The global burden of non-alcoholic fatty liver disease (NAFLD) parallels the
increase in obesity rates across the world. Although overweight and obesity status are …
increase in obesity rates across the world. Although overweight and obesity status are …
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
SA Harrison, R Taub, GW Neff, KJ Lucas, D Labriola… - Nature medicine, 2023 - nature.com
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease–novel insights into cellular communication circuits
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and is
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
emerging as the leading cause of cirrhosis, liver transplantation and hepatocellular …
A global view of the interplay between non-alcoholic fatty liver disease and diabetes
N Stefan, K Cusi - The lancet Diabetes & endocrinology, 2022 - thelancet.com
Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …
[HTML][HTML] 4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - ncbi.nlm.nih.gov
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association
Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the …
A Gastaldelli, K Cusi, LF Landó, R Bray… - The lancet Diabetes & …, 2022 - thelancet.com
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP)
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …
and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 …